Cello Health BioConsulting
  • menu
  • Home
  • About us
    • Why We’re Different
    • Our Team
    • Mission, Vision & Values
  • Capabilities
    • Common Client Dilemmas
    • Opportunity Assessments
    • Opportunity Search and Evaluation
    • Portfolio and Platform Strategy
    • Business Development & Partnering Strategy
    • Market Access Strategy
    • Early Stage Strategy
  • Our Insights
    • News
    • Presentations
    • Testimonials
    • Events
  • Careers
    • Current Opportunities
    • A Day in the Life
    • Our Culture
NK cell therapy player Artiva makes some more noise, pulling in $120M Series B less than a month after Merck deal

NK cell therapy player Artiva makes some more noise, pulling in $120M Series B less than a month after Merck deal

View Article +
IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

View Article +
In an apparent R&D about-face, Eli Lilly partners with Precision BioSciences on genome editing in a deal worth up to nearly $2.7B

In an apparent R&D about-face, Eli Lilly partners with Precision BioSciences on genome editing in a deal worth up to nearly $2.7B

View Article +
Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer competitors

Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer competitors

View Article +
Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO

Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO

View Article +
eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors

eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors

View Article +
Beacon Adoptive Cell Newsletter: Regenerative Medicine Advanced Therapy Designation For Ilixadencel

Beacon Adoptive Cell Newsletter: Regenerative Medicine Advanced Therapy Designation For Ilixadencel

View Article +
IDO-derived cancer vaccine scores in combo trial with Keytruda

IDO-derived cancer vaccine scores in combo trial with Keytruda

View Article +
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma

Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma

View Article +
KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

View Article +
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. 6
  8. 7
  9. 8
  10. →

Search

Elsewhere

Let’s work together

Contact us

  • Cello Health BioConsulting
  • 25-B Hanover Road
  • Suite 320
  • Florham Park, NJ
  • 07932
  • USA
  • +1 973 292 5001
  •  
  • Part of Cello Health plc

    Follow us

    Cello Health BioConsulting

    ©2021 Defined Health, now known as Cello Health BioConsulting | Privacy policy.

    View Presentation

    View Presentation

    Please fill the form to access the presentation.
    • This field is for validation purposes and should be left unchanged.

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in settings.

    Defined Health, now known as Cello Health BioConsulting
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

    3rd Party Cookies

    This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

    Keeping this cookie enabled helps us to improve our website.

    Please enable Strictly Necessary Cookies first so that we can save your preferences!